Zimmer Biomet Holdings Inc ZBH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
Zimmer Biomet Announces Third Quarter 2026 Financial Results
Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
Trading Information
- Previous Close Price
- CHF 75.00
- Day Range
- CHF 76.00–76.00
- 52-Week Range
- CHF 62.50–77.50
- Bid/Ask
- CHF 85.50 / CHF 87.50
- Shares Outstanding
- 189.25M
- Market Cap
- $14.50B
- Volume/Avg
- 34 / 24
Key Statistics
- Price/Earnings (Normalized)
- 16.63
- Price/Sales
- 2.48
- Dividend Yield (Trailing)
- 0.88%
- Dividend Yield (Forward)
- 0.91%
- Dividend Payment Schedule
- Jan, Apr, Jul, Oct
- Total Yield
- 4.93%
Company Profile
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The company has assembled a wide array of robotic platforms, and it spun out its dental and spine businesses in 2022.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Value
- Total Number of Employees
- 17,000
- Website
- https://www.zimmerbiomet.com
Competitors
Valuation
Metric | ZBH | SNN | SYK |
|---|---|---|---|
Price/Earnings (Normalized) | 16.63 | 16.09 | 22.82 |
Price/Book Value | 1.56 | 2.54 | 5.29 |
Price/Sales | 2.48 | 2.13 | 4.78 |
Price/Cash Flow | 11.26 | 10.94 | 23.41 |
Price/Earnings
ZBH
SNN
SYK
Financial Strength
Metric | ZBH | SNN | SYK |
|---|---|---|---|
Quick Ratio | 0.63 | 1.11 | 1.07 |
Current Ratio | 1.46 | 2.14 | 2.18 |
Interest Coverage | 4.07 | 5.42 | 9.73 |
Quick Ratio
ZBH
SNN
SYK
Profitability
Metric | ZBH | SNN | SYK |
|---|---|---|---|
Return on Assets (Normalized) | 7.14% | 8.51% | 11.66% |
Return on Equity (Normalized) | 13.01% | 17.09% | 24.04% |
Return on Invested Capital (Normalized) | 9.36% | 11.66% | 15.46% |
Return on Assets
ZBH
SNN
SYK
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|^>cGNZ@ | LOCK|C@rk | $190B | |||
| Medtronic PLC MDT | LOCK|@Fdl<P | LOCK|!#zJ | $130B | |||
| Stryker Corp SYK | LOCK|#Z<mVG<< | LOCK|&@ | $124B | |||
| Boston Scientific Corp BSX | LOCK|?^pBkT | LOCK|VGdNL | $62B | |||
| Edwards Lifesciences Corp EW | LOCK|^pk@P>J | LOCK|VPMkp | $59B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|^^@z%Cf | LOCK|V!% | $37B | |||
| Koninklijke Philips NV ADR PHG | LOCK|^n | LOCK|&j | $30B | |||
| DexCom Inc DXCM | LOCK|#%g?Fb&$ | LOCK|ZL$KB | $30B | |||
| Steris PLC STE | LOCK|K>qK?Vf | LOCK|<>rb | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|lxc#yLS< | LOCK|sr | $20B |
United States